Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer

Background: Folate receptor alpha (FRα), commonly expressed in epithelial ovarian cancers, is a clinically actionable biomarker following approval of the antibody–drug conjugate mirvetuximab soravtansine (MIRV). Pivotal trials showed that high FRα expression predicts MIRV benefit, creating the need...

Descripción completa

Detalles Bibliográficos

Autores principales:	Kim Ma, Basile Tessier-Cloutier, Alon D. Altman, Mark S. Carey, Josee-Lyne Ethier, Susie Lau, Cheng-Han Lee, Laura Hopkins, Katharina Kieser, Aalok Kumar, Shuk On Annie Leung, Julie M. V. Nguyen, Helen MacKay, Jacob McGee, Lina Salman, Shannon Salvador, Cidalia Sluce, Luiza Tatar, Alicia A. Tone, Anna Tinker, Elizabeth Tremblay, Ana C. Veneziani, Danielle Vicus, Stephen Welch, Sharon Windsor Harker, Melica Nourmoussavi Brodeur
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2026-06-01
Colección:	Current Oncology
Materias:	epithelial ovarian cancer folate receptor alpha mirvetuximab soravtansine consensus statement companion diagnostics
Acceso en línea:	https://www.mdpi.com/1718-7729/33/6/330
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!